We found that LMB-100 treatment caused a dose-dependent decrease in conditioned medium VEGF concentration in KLM1, T3M4 and AsPC1 pancreatic cancer cell lines (Figure 2B). Here, VEGFA is linked to pancreatic neoplasm.